Cargando…
Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy
OBJECTIVE: The aim of this study is to determine the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) among adult patients treated with biologic agents or small molecules for chronic inflammatory rheumatic diseases, in particular for chronic inflamma...
Autores principales: | Quartuccio, Luca, Valent, Francesca, Pasut, Enrico, Tascini, Carlo, De Vita, Salvatore |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Masson SAS on behalf of Société française de rhumatologie.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239017/ https://www.ncbi.nlm.nih.gov/pubmed/32445935 http://dx.doi.org/10.1016/j.jbspin.2020.05.003 |
Ejemplares similares
-
Prévalence du COVID-19 chez les patients atteints de rhumatismes inflammatoires chroniques traités par biothérapies ou inhibiteurs des JAK : une étude basée sur la population au cours des deux premiers mois de l’épidémie de COVID-19 en Italie()
por: Quartuccio, Luca, et al.
Publicado: (2021) -
Safety of Biologic-DMARDs in Rheumatic Musculoskeletal Disorders: A Population-Based Study over the First Two Waves of COVID-19 Outbreak
por: Sonaglia, Arianna, et al.
Publicado: (2022) -
Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases
por: Quartuccio, Luca, et al.
Publicado: (2020) -
Pattern of vascular disease in Lombardy, Italy, during the first month of the COVID-19 outbreak
por: Melissano, Germano, et al.
Publicado: (2020) -
Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
por: Santos, Cristiana Sieiro, et al.
Publicado: (2021)